| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
PEGs
Boc-NH-PEG7-acetic acid targets the chemical conjugation process rather than biological receptors. As a bifunctional linker, its target is the formation of stable amide bonds between the carboxylic acid group and amine-containing protein-targeting ligands, and between the deprotected amine and E3 ligase ligands bearing carboxyl groups. In PROTAC applications, the assembled molecule targets specific disease-related proteins for ubiquitination and degradation via the proteasome pathway. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
Boc-NH-PEG7-acetic acid does not exhibit direct biological "activity" as it is a synthetic building block. Its in vitro utility is demonstrated indirectly through the PROTAC molecules assembled using this linker. For example, PROTACs incorporating this PEG7 linker have shown enhanced solubility and degradation efficiency against target proteins such as BRD4 compared to shorter PEG linkers, due to improved flexibility and reduced steric hindrance. |
| ln Vivo |
In vivo activity of Boc-NH-PEG7-acetic acid is evaluated through the PROTACs constructed with this linker. PEG7-based PROTACs typically exhibit improved pharmacokinetic properties, including prolonged plasma half-life and reduced immunogenicity, attributed to the hydrophilic and non-immunogenic nature of the PEG spacer. In rodent xenograft models, PROTACs using this linker have demonstrated effective tumor growth inhibition via targeted protein degradation.
|
| Enzyme Assay |
A typical conjugation assay involves activating the terminal carboxylic acid using EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and NHS (N-hydroxysuccinimide) in anhydrous DMF or DMSO at room temperature for 2 hours. The activated NHS ester is then reacted with an amine-containing protein-targeting ligand (1:1 molar ratio) in the presence of DIPEA at room temperature overnight. The Boc group is subsequently removed with TFA in DCM (1:1) for 1 hour.
|
| Cell Assay |
Cellular assays are not performed directly on Boc-NH-PEG7-acetic acid. Instead, cells (e.g., HEK293T or HeLa) are treated with the final PROTAC construct (0.1-10 uM, 24-48 hours) assembled using this linker. After treatment, cells are lysed, and target protein levels are analyzed by Western blotting using specific antibodies. GAPDH or beta-actin serves as loading control. Degradation efficiency (DC50) and maximum degradation (Dmax) are calculated.
|
| Animal Protocol |
In vivo experiments utilize PROTAC molecules synthesized with this PEG7 linker. In mouse xenograft models (e.g., BRD4-dependent cancer models), the PROTAC is administered via intraperitoneal or oral route at doses of 10-50 mg/kg, typically daily or every other day for 14-21 days. Tumor volumes are measured every 2-3 days using calipers. At study termination, tumors are harvested and analyzed for target protein degradation by Western blot and immunohistochemistry.
|
| ADME/Pharmacokinetics |
As a PROTAC linker rather than a therapeutic agent, Boc-NH-PEG7-acetic acid itself lacks an absorption-distribution-metabolism-excretion profile. However, the PEG7 linker significantly influences the pharmacokinetics of the final PROTAC. PEGylation reduces plasma protein binding, decreases renal clearance, and extends half-life. PEG7-containing PROTACs typically show moderate oral bioavailability (20-40% in rodents) and plasma half-life of 2-6 hours.
|
| Toxicity/Toxicokinetics |
Boc-NH-PEG7-acetic acid is classified as a laboratory reagent and poses minimal toxicity when handled with standard precautions. The compound is not intended for human consumption. Acute oral toxicity is expected to be low (LD50 > 2000 mg/kg in rodents). Potential hazards include mild skin and eye irritation. The Boc protecting group is stable under physiological conditions but releases CO2 and isobutylene upon strong acid treatment. Standard safety practices (gloves, lab coat, eye protection) apply.
|
| References | |
| Additional Infomation |
Boc-NH-PEG7-acetic acid (CAS: 141282-29-3) is a research-grade PROTAC linker with a purity of ≥98%. It is classified as a heterobifunctional PEG linker used in chemical biology and drug discovery. This compound is typically stored as a solid at -20degC, protected from moisture. It is soluble in DMSO, DMF, and dichloromethane but has limited water solubility due to the Boc group. Its high PEG chain length (7 units) provides optimal solubility and flexibility for PROTAC applications. It is not an approved drug and is intended for research only.
|
| Molecular Formula |
C21H41NO11
|
|---|---|
| Molecular Weight |
483.550348043442
|
| Exact Mass |
483.267
|
| CAS # |
141282-29-3
|
| PubChem CID |
53983441
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
33
|
| Complexity |
472
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(OC(C)(C)C)(=O)NCCOCCOCCOCCOCCOCCOCCOCC(O)=O
|
| InChi Key |
JZVPPASVRSYVSR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H41NO11/c1-21(2,3)33-20(25)22-4-5-26-6-7-27-8-9-28-10-11-29-12-13-30-14-15-31-16-17-32-18-19(23)24/h4-18H2,1-3H3,(H,22,25)(H,23,24)
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0680 mL | 10.3402 mL | 20.6804 mL | |
| 5 mM | 0.4136 mL | 2.0680 mL | 4.1361 mL | |
| 10 mM | 0.2068 mL | 1.0340 mL | 2.0680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
